The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving

The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
复制标题

DOI:
10.1016/j.biopsych.2019.05.021
复制
发表时间:
2019-12-01
影响因子:
10.6
通讯作者:
Krishnan-Sarin, Suchitra
Krishnan-Sarin, Suchitra
中科院分区:
医学1区
文献类型:
--
作者:
de Laat, Bart;Goldberg, Alissa;Krishnan-Sarin, Suchitra

文献摘要

被引文献

相似文献

背景:纳曲酮是一种非选择性阿片受体拮抗剂,用于治疗酒精使用障碍。然而,仅观察到适度的临床效果,可能是因为对影响纳曲酮功效的生物学变量的了解有限。我们研究了 kappa 阿片受体 (KOR) 在纳曲酮治疗效果中的潜在作用。 方法:总共 48 名符合 DSM-IV 酒精依赖标准的非寻求治疗的重度饮酒者(16 名女性)参加了两种饮酒模式 (ADP),中间间隔一周开放标签纳曲酮(每天 100 毫克)。使用酒精冲动问卷和耶鲁渴望量表评估渴望,并在每个 ADP 中记录饮酒行为。在开始纳曲酮之前,使用 [C-11]LY2795050 正电子发射断层扫描确定杏仁核、海马、苍白球、纹状体、扣带皮层和前额叶皮层中 KOR 的可用性。 结果:参与者报告的渴望水平较低(耶鲁大学渴望量表:-11 +/- 1,p < .0001;酒精冲动问卷:在纳曲酮治疗后的第二次 ADP 期间,摄入量减少了 -6 +/- 0.6,p < .0001)并减少了饮酒量(-3.7 +/- 4,p < .0001)。观察到的饮酒减少与纹状体 (p = .005)、苍白球 (p = .023) 和扣带皮层 (p = .018) 的基线 KOR 可用性呈负相关。体素分析确定了双侧岛叶、前额叶和扣带皮层中与饮酒减少相关的簇 (p < .0001)。此外,所有评估的大脑区域中 KOR 的可用性都与两个 ADP 中测量的渴望相关。结论:KOR 与酒精使用障碍纳曲酮治疗后的饮酒和渴望有关。
BACKGROUND: Naltrexone is a nonselective opioid receptor antagonist used as a treatment for alcohol use disorder. However, only modest clinical effects have been observed, possibly because of limited knowledge about the biological variables affecting the efficacy of naltrexone. We investigated the potential role of the kappa opioid receptor (KOR) in the therapeutic effect of naltrexone.METHODS: A total of 48 non-treatment-seeking heavy drinkers (16 women) who met DSM-IV criteria for alcohol dependence participated in two alcohol drinking paradigms (ADPs) separated by a week of open-label naltrexone (100 mg daily). Craving, assessed with the Alcohol Urge Questionnaire and the Yale Craving Scale, and drinking behavior were recorded in each ADP. Prior to naltrexone initiation, KOR availability was determined in the amygdala, hippocampus, pallidum, striatum, cingulate cortex, and prefrontal cortex using positron emission tomography with [C-11]LY2795050.RESULTS: Participants reported lower levels of craving (Yale Craving Scale: -11 +/- 1, p < .0001; Alcohol Urge Questionnaire: -6 +/- 0.6, p < .0001) and consumed fewer drinks (-3.7 +/- 4, p < .0001) during the second ADP following naltrexone therapy. The observed reduction in drinking was negatively associated with baseline KOR availability in the striatum (p = .005), pallidum (p = .023), and cingulate cortex (p = .018). Voxelwise analysis identified clusters in the bilateral insula, prefrontal, and cingulate cortex associated with the reduction in drinking (p < .0001). In addition, KOR availability in all evaluated brain regions was associated with craving measured in both ADPs.CONCLUSIONS: The KOR is implicated in drinking and craving following naltrexone therapy in alcohol use disorder.